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ABSTRACT 
BACKGROUND: International guidelines recommend the use of angiotensin- 
converting enzyme inhibitors, possibly in combination with other antihypertensive 
drugs, to treat hypertension with associated risk factors. 
OBJECT IVE:  The aim of this study was to compare the antihypertensive effect of 
the combination of zofenopril plus hydrochlorothiazide v rsus zofenopril monotherapy 
in patients with essential hypertension, according to their cardiovascular risk level. 
METHODS:  This was a post hoc analysis of a previously published efficacy and 
tolerability study. After a 4-week placebo washout, patients with mild to moderate 
essential hypertension (diastolic blood pressure [DBP] 95-115 mm Hg), aged 18 to 
75 years, were randomized at a ratio of 2:1:1 to treatment with zofenopril 30 mg plus 
hydrochlorothiazide 12.5 mg or monotherapy with zofenopril 30 mg or hydrochlorothi- 
azide 12.5 mg for 12 weeks in an international, multicenter, double-blind study. This 
period was followed by 24 weeks of open-label treatment. Systolic BP [SBP] and DBP 
were measured by mercury sphygmomanometry, and changes associated with treatment 
were calculated. Patients' cardiovascular risk was computed using the Heart Score algo- 
rithm. Patients were classified in quartiles according to distribution of cardiovascular 
risk level, and comparisons were limited to the zofenopril plus hydrochlorothiazide and 
zofenopril monotherapy treatment groups. The primary end point was change in office 
DBP. 
RESULTS:  Two hundred forty-six patients (139 men, 107 women; mean [SD] age, 
54 [11] years) were included in the analysis. Mean baseline cardiovascular risk was simi- 
lar in the zofenopril plus hydrochlorothiazide group and the zofenopril monotherapy 
group (7% vs 9%). DBP and SBP reductions with treatment were significantly greater 
(both, P < 0.01) with combination treatment than with monotherapy for each quartile 
of cardiovascular risk. Cardiovascular risk reduction at the end of the 12 weeks of 
double-blind treatment was greater in the zofenopril plus hydrochlorothiazide group 
than in the zofenopril monotherapy group (1.9% vs 0.2%; P < 0.01), particularly in the 
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group of patients with the highest cardiovascular risk at baseline (5.2% vs 2.0%). At 
the end of the 24-week open-label treatment period, the mean reduction in cardiovas- 
cular risk was also significantly greater in the combination treatment group than in the 
monotherapy group (1.4% vs 0.5%; P < 0.01). 
CONCLUSIONS: In these hypertensive patients, combination treatment with 
zofenopril plus hydrochlorothiazide was associated with a significantly greater decrease 
in BP compared with zofenopril monotherapy, regardless of the patient's cardiovas- 
cular risk. The difference between combination treatment and monotherapy was 
particularly evident for the group of patients at highest risk. (Curr Ther Res Clin Exp. 
2008;69:232-242) © 2008 Excerpta Medica Inc. 
KEY WORDS:  essential hypertension, cardiovascular isk, zofenopril, 
hydrochlorothiazide. 
INTRODUCTION 
International guidelines 1,2 recommend the use of angiotensin-converting e zyme (ACE) 
inhibitors, possibly in combination with other antihypertensive drugs, to treat hyper- 
tension with associated risk factors because of their renoprotective, vascular, and cardio- 
protective ffects. In more than half of high-risk hypertensive patients adequate blood 
pressure (BP) control is difficult to achieve with a single antihypertensive drug3 -3 
Zofenopril, a sulfhydryl ACE inhibitor, is characterized by high lipophilicity, sus- 
tained cardiac ACE inhibition, and promotional ntioxidant and tissue-protective prop- 
erties. 4-7 Its selective, long-acting ACE inhibitory activity makes it effective and well- 
tolerated for the treatment of a number of cardiovascular diseases (eg, acute myocardial 
infarction, 8-1° heart failure, 11,12 and essential hypertensionl3-16). When combined with 
low-dose hydrochlorothiazide (12.5 mg), zofenopril 30 mg showed an additional 4- to 
8-mm Hg antihypertensive effect with favorable tolerability, in line with that of other 
combinations of an ACE inhibitor and low-dose hydrochlorothiazide. 17,18 Zofenopril 
plus hydrochlorothiazide might be particularly useful in high-risk patients, such as 
those with metabolic syndrome39 
The present paper reports the results of a post hoc analysis of a 12-week, double- 
blind, randomized, parallel-group study with a 24-week, open-label follow-up phase. 
The main study 18 found a significantly greater mean (SD) office diastolic BP (DBP) 
reduction (primary study objective) with the combination of zofenopril 30 mg plus 
hydrochlorothiazide 12.5 mg (14 [9] mm Hg) than with monotherapy with zofenopril 
30 mg (10 [8] mm Hg) or hydrochlorothiazide 12.5 mg (10 [9] mm Hg) alone. The 
safety profile of zofenopril plus hydrochlorothiazide id not differ significantly from 
that obtained with the corresponding monotherapies (24% of patients with drug-related 
adverse events vs 20% with zofenopril alone and 17% with hydrochlorothiazide 
alone). 
The aim of this post hoc analysis was to compare the antihypertensive effect of the 
combination of zofenopril plus hydrochlorothiazide versus zofenopril alone in patients 
with essential hypertension, some of whom had metabolic syndrome, 19according to 
their cardiovascular risk level using the Heart Score algorithm. 2° 
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PAT IENTS AND METHODS 
STUDY POPULAT ION 
Written informed consent was obtained from all patients prior to their inclusion 
in the study. The study was approved by the independent institutional review boards 
of the centers involved. The original study 18 assessed consecutive outpatients of either 
gender with mild to moderate ssential hypertension. No patient was compensated, 
reimbursed, or paid for treatment or for participation i the study. Patients were eligible 
for the study if they were aged 18 to 75 years and had an office sitting systolic blood 
pressure (SBP) of_<240 mm Hg and DBP of 95 to 115 mm Hg after 4 weeks of placebo 
washout from previous antihypertensive tr atment. Patients were excluded if they had 
any of the following: (1) a difference in office sitting DBP >10 mm Hg between the 
screening and randomization visits; (2) secondary or malignant hypertension; (3) clini- 
cally significant heart disease (cardiac valvular disease, cardiac arrest, unstable angina, 
or myocardial infarction in the previous 6 months); (4) cerebrovascular disease; (5) renal 
insufficiency (serum creatinine concentration >1.8 mg/dL); (6) known or suspected reno- 
vascular disease; (7) inadequately controlled type 1 or 2 diabetes mellitus; (8) a history 
of malignancy in the previous 5 years; (9) severe hepatic impairment; (10) a history of 
alcohol or drug abuse; or (11) known hypersensitivity o ACE inhibitors or thiazide 
diuretics. Pregnant or breast-feeding women and women of childbearing potential who 
were not practicing an effective method of birth control were also excluded. During the 
study, use of antihypertensive drugs other than the study drugs was not allowed. 
STUDY DES IGN 
This was a post hoc analysis of an international (France, United Kingdom, The 
Netherlands, Belgium, and Poland), multicenter (58 centers), randomized, ouble-blind, 
parallel-group study. A 4-week placebo washout period, during which previous anti- 
hypertensive treatment had to be withdrawn, was followed by 12 weeks of randomized 
treatment with zofenopril 30 mg plus hydrochlorothiazide 12.5 mg or monotherapy 
with zofenopril 30 mg or hydrochlorothiazide 12.5 mg. Patients were randomized in 
a ratio of 2:1:1. Randomization was done by blocks and generated by a computer. The 
patient randomization numbers were allocated sequentially by center in the order in 
which the patients entered the study. Each investigator had an envelope containing 
the information eeded to break the randomization code; the envelope was stored in a 
secure place and was to be opened in case of emergency. Blinding of the physicians and 
the patients was ensured using a double-dummy technique in which each dose con- 
sisted of 2 identical-looking pills. The drugs were administered QD between 9 aM and 
11 AM. The initial 12-week treatment period was the efficacy phase of the study, which 
was followed by a 24-week period during which only tolerability was assessed. 
At the screening visit, a medical history was collected and a full physical examina- 
tion, 12-lead electrocardiogram (ECG), and informed consent were obtained. ECGs were 
assessed again at randomization and after 12 and 36 weeks of treatment. Hematology, 
biochemistry, and urinalysis were performed at screening, at randomization, and after 
12 and 36 weeks of treatment. After 4 weeks of treatment, a reduced laboratory assess- 
ment (blood urea nitrogen and serum creatinine and electrolyte concentrations) was also 
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carried out. Patients were seen 4, 8, 12, 24, and 36 weeks after randomization. During 
these visits and at screening and at randomization, BP, heart rate, and adverse vents 
(AEs) were assessed. Compliance to treatment was assessed at each study visit by count- 
ing returned pills. 
BLOOD PRESSURE AND HEART RATE MEASUREMENT 
BP was measured in the clinic using a standard sphygmomanometer 24 hours after 
the last drug dose was administered. Three measurements taken at 2-minute intervals 
after 10 minutes of rest in the sitting position were averaged and used as the office BP 
reference value during the first 12 weeks of the study. During the 24-week tolerability 
phase, a single BP reading was collected at each visit. SBP and DBP values were taken 
at the first and fifth Korotkoff sounds, respectively. Heart rate was measured by palpat- 
ing the radial artery pulse. 
STAT IST ICAL  ANALYS IS  
The present study is a post hoc analysis of a main efficacy and safety trial 18 performed 
in patients classified according to their cardiovascular risk level, computed using the 
Heart Score algorithm, which takes into account age, sex, total cholesterol levels, SBP, 
and patient's moking status. 2° 
We limited the analysis to a comparison of the zofenopril plus hydrochlorothiazide 
group with the zofenopril monotherapy group. The analysis was performed on patients 
who were valid according to the protocol (ie, all randomized patients who completed the 
12-week study period plus the open-label follow-up without major protocol violations). 
We used the same primary end point as that of the main study--change in office 
DBP. In this post hoc analysis we classified patients in quartiles of cardiovascular risk 
level (risk of developing a cardiovascular disease in the next 10 years; quartile 1 = lowest 
risk to quartile 4 = highest risk). 2° At baseline and at the end of the 12-week treatment 
period, office sitting SBP and DBP and mean cardiovascular risk levels were computed. 
Changes in baseline office BP and cardiovascular risk level were determined after the 
12-week treatment phase. The effect of drug treatment on cardiovascular risk was also 
assessed for the open-label period. No tolerability analysis was performed because of the 
post hoc nature of this study and the main study objective. 
All variables were compared between treatments using analysis of variance, with 
analysis for repeated measures when comparison was made across quartiles. P < 0.05 
was considered statistically significant. Data are reported as mean (SD). 
RESULTS 
DEMOGRAPHIC  AND CL IN ICAL  DATA 
Three hundred fifty patients were randomized to zofenopril 30 mg plus hydrochlo- 
rothiazide 12.5 mg (n = 235) or to zofenopril 30 mg (n = 115). Of these patients, 
256 (73.1%) completed the 12-week randomized phase plus the 24-week open-label 
phase without protocol violations and thus were included in the per protocol analysis. 
The main reason for premature study discontinuation was the occurrence of AEs 
(6% in the zofenopril plus hydrochlorothiazide group vs 9% in the zofenopril mono- 
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therapy group); data were not available to calculate cardiovascular risk for 10 patients, 
and thus the final per protocol population for this post hoc analysis comprised 
246 patients (157 zofenopril plus hydrochlorothiazide and 89 zofenopril monotherapy; 
139 men, 107 women; mean [SD] age, 54 [11] years). 
All baseline demographic and clinical data were comparable between treatment 
groups (Table). The mean baseline risk for developing cardiovascular disease in the next 
10 years was 0.5% for the first quartile, 2.2% for the second, 7.1% for the third, and 
19.9% for the fourth, with no statistically significant difference between the 2 treat- 
ment groups in the percentage of risk. 
OFFICE BLOOD PRESSURE CHANGES 
Office sitting DBP and SBP reductions after 12 weeks of double-blind treatment, 
according to quartiles of baseline cardiovascular risk, were significantly greater (all, 
P < 0.01) in the group receiving zofenopril plus hydrochlorothiazide than in the zofeno- 
pril monotherapy group (Figure 1). The difference between combination treatment and 
monotherapy was particularly evident for the group of patients at highest risk. 
CARDIOVASCULAR RISK LEVEL 
Mean baseline cardiovascular risk was similar in the zofenopril plus hydrochloro- 
thiazide group and the zofenopril monotherapy group (7% vs 9%). Cardiovascular risk 
reduction at the end of the 12 weeks of double-blind treatment was significantly greater 
in the zofenopril plus hydrochlorothiazide group than in the zofenopril monotherapy 
group (1.9% vs 0.2%; P < 0.01), particularly in the group of patients with the highest 
cardiovascular risk at baseline (5.2% vs 2.0%). At the end of the 24-week open-label 
Table. Baseline demographic and clinical characteristics of the study patients random- 
ized to zofenopril 30 mg plus hydrochlorothlazide 12.5 mg or zofenopril 30 mg 
monotherapy (N = 246).* Data are mean (SD) unless otherwise specified. 
Characteristic 
Zofenopril + Zofenopril 
Hydrochlorothiazide Monotherapy 
(n = 157) (n = 89) 
Age, y 53 (11) 54 (11) 
Sex, no. (%) 
Male 92 (59) 47 (53) 
Female 65 (41) 42 (47) 
DBP, mm Hg 101 (4) 101 (4) 
SBP, mm Hg 161 (14) 158 (13) 
HR, beats/min 74 (9) 73 (9) 
Cardiovascular isk level, % 7 (7) 9 (12) 
Low cardiovascular isk (_<5%), no. (%) 88 (56) 43 (48) 
High cardiovascular isk (>5%), no. (%) 69 (44) 46 (52) 
DBP = diastolic blood pressure; SBP = systolic blood pressure; HR = heart rate. 
*No significant between-group differences were found. 
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Figure 1. Reductions In mean (SD) office (A) diastolic blood pressure (DBP) and (B) sitting 
systolic BP (SBP) after 12 weeks of treatment, by quartiles of cardiovascular 
risk level (quartile 1 = lowest risk to quartile 4 = highest risk), in patients 
treated with zofenopril 30 mg plus hydrochlorothiazide 12.5 mg (n = 157) and 
zofenopril 30 mg (n = 89). P refers to the statistical significance of the trend 
of the difference between combination treatment and monotherapy over the 
4 quartlles as determined by analysis of variance. 
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treatment period, the mean reduction in cardiovascular risk was also significantly 
greater in the combination treatment group than in the monotherapy group (1.4% vs 
0.5%; P < 0.01), 
In patients treated with zofenopril plus bydrochlorothiazide, a significantly greater 
(P < 0.01) reduction in 10-year isk of cardiovascular disease was observed in patients 
in the higher-risk quartiles (Figure 2). Of the 44 patients at high cardiovascular risk 
(>5%) at baseline, 22 (50%) had their risk reduced to a low level (---5%) after 12 weeks 
of treatment. The change in risk after treatment was significantly different compared 
with baseline (P < 0.01). 
DISCUSSION 
In these patients with essential hypertension, combination treatment with zofenopril 
plus hydrochlorothiazide was associated with greater BP reduction than treatment with 
zofenopril alone. The drug combination was significantly better for different levels of 
cardiovascular risk, particularly for SBE In patients with the highest level of cardiovas- 
cular risk, the between-treatment difference was greatest, suggesting that these patients 
may benefit more from combination treatment. 
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Figure 2. Mean cardiovascular risk at baseline and after 12 weeks of treatment, by 
quartiles of cardiovascular risk level (quartile 1 = lowest risk to quartile 4 = 
highest risk), in patients treated with zofenopri130 mg plus hydrochlorothiazide 
12.5 mg (n : 157). The relative risk reduction (RRR) after treatment compared 
to baseline (%) is shown below each quartile. P refers to the statistical 
significance of the trend of the difference between baseline and treatment 
over the 4 quartiles as determined by analysis of variance. 
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Previous studies 21-23 have shown that hypertensive patients at highest risk have a 
greater chance of being resistant to monotherapy. Therefore, they require combination 
drug treatment to achieve adequate BP control and protection from cardiovascular 
events. For instance, in the Valsartan Antihypertensive Long-term Use Evaluation 
(VALUE) study, 21 which enrolled 15,245 treated and untreated hypertensive patients 
at high risk of cardiovascular events, amajority of patients (59%) were receiving treat- 
ment with ->2 antihypertensive drugs at study end (including randomized treatment 
with valsartan or amlodipine). After a mean follow-up of 4.2 years, the overall mean 
SBP and DBP were 138 and 78 mm Hg, respectively (with a reduction of 10%-11% 
and 9%-11%), a cardiac morbidity o f -8%,  and a rate of cerebrovascular ccident 
of 4%. In the Controlled Onset Verapamil Investigation of Cardiovascular End 
Points (CONVINCE) trial, 22 which enrolled 16,602 hypertensive patients with 
_>1 additional risk factor for cardiovascular disease who were randomized to vera- 
pamil, atenolol, or hydrochlorothiazide, after a median follow-up of 3 years 80% of 
patients were taking combination treatment. The mean BP at the end of treatment 
was 137 mm Hg (systolic) and 79 mm Hg (diastolic) in all treatment groups, with a 
reduction of 9% and 8% to 9%, respectively, and a cardiovascular events rate of 9% 
to 10%. In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart 
Attack Trial (ALLHAT) study, 23 33,357 patients with hypertension and __.1 other 
cardiovascular risk factor were treated for 4.9 years with chlorthalidone, amlodipine, 
or lisinopril, and -40% were receiving combination treatment. The BP achieved in 
all treatment groups at study end was 135 mm Hg (systolic) and 75 mm Hg (dia- 
stolic), with an 8% and 11% reduction, respectively, and with a rate of fatal and 
nonfatal cardiovascular events of 11% to 12%. 
In the present study, patients administered combination treatment who had a com- 
parable predicted risk of cardiovascular diseases (3rd and 4th quartiles) achieved SBP 
and relative reduction from baseline that were similar to those observed in the afore- 
mentioned studies (140 mm Hg and 14%, respectively), although DBP was numerically 
higher (87 mm Hg with a 14% reduction). This suggests that relatively short-term 
treatment with an ACE inhibitor and a diuretic, in patients classified as being at high 
risk according to the Heart Score algorithm, 2° might yield advantages similar to those 
observed in long-term, outcome-based trials of high-risk hypertensive patients receiving 
multiple drug treatment. It also supports current international guidelines I that identify 
the combination of an ACE inhibitor plus a diuretic as first-line treatment for higher- 
risk hypertensive patients in whom a more prompt and consistent antihypertensive 
effect is desirable. 
Another finding of this study was the effect of combination therapy on cardiovas- 
cular risk level, which was reduced in high-risk patients, with half of the patients at 
high risk 2° moving to the low-risk category after 12 weeks of treatment. The positive 
effect of the combination treatment and its significant effect versus monotherapy were 
maintained uring the 24-week open-label period. 
A possible explanation for the overall good antihypertensive effect of the combina- 
tion of zofenopril plus hydrochlorothiazide n hypertensive patients at risk for cardio- 
vascular diseases may be its sustained and consistent BP control over 24 hours ~4,t7 and 
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zofenopril's antioxidant activity, which may reduce ndothelial ctivation in hyperten- 
sive patients and thus may provide vascular and cardiac protection. 4,~4 
This post hoc analysis is based on a subgroup of the patients in a published trial, 
and thus a specific sample size calculation was not made. Another limitation was a 
high patient dropout rate during the study, especially during the double-blind phase, 
mainly due to the occurrence ofAEs. Finally, the sample size of the analysis was limited 
because only the per protocol population was included. All these limitations may have 
introduced potential bias in the interpretation f study results; therefore, a study with 
an adequate sample size should be conducted to confirm our findings. 
CONCLUSIONS 
In these hypertensive patients, combination treatment with zofenopril plus hydrochloro- 
thiazide was associated with a significantly greater decrease in BP compared with zofeno- 
pril monotherapy, regardless of the patient's cardiovascular risk. In this relatively short 
period of time, the combination therapy appeared to be effective in reducing cardiovascu- 
lar risk level in individuals with varying levels of cardiovascular risk at baseline, with 
larger eductions being observed in patients at highest risk for cardiovascular events. 
ACKNOWLEDGMENTS 
This article was written with financial assistance from Menarini Industrie Farmaceutiche 
Riunite (Firenze, Italy) and Istituto Lusofarmaco d'Italia S.p.A (Milano, Italy). 
Drs. Malacco and Omboni have served as occasional consultants for Menarini 
Industrie Farmaceutiche Riunite and Istituto Lusofarmaco d'Italia. Dr. Omboni per- 
formed all of the statistical analyses; writing was done by both authors. 
The study participants were as follows: Coordinators: Drs. Becq (France), van Nes (The 
Netherlands), Zaleska (Poland), Blagden (United Kingdom); Belgium: Drs. Capiau, 
D'hoohhe, Debruyne, Haerens, Loos; United Kingdom: Drs. Baskaran, Bremner, Burton, 
Canning, Hosie, Hughes, Hutchison, Kansagra, Lane, Leak, Lee, Lee PS, Dauncey, 
Maksimczyk, Orpen, Pimm, Scott, Eavis, Walzer, Lightstone; Poland: Drs. Achremczyk, 
Burduk, Dabrowski, Wojciechowski, Gessek, Jaworska, Kawka-Urbanek, Kolodziej, 
Maciejewicz, Malinski, Marcinowska-Suchowierska, N rtowicz, Piotrowski, Ruminski, 
Smiciak-Korombel; The Netherlands: Drs. Bonanius, Burgers, Croughs, De Ruitter, 
Dikschei, Ferguson, Passage, Veerman; France: Drs. Beignol-Devalmont, Ripoll, Dumond, 
Rousset, Flosi, Dreyfus, Havy, Burguier, B~ard, and Colombani. 
REFERENCES 
1. Mancia G, De Backer G, Dominiczak A, et al, for the Management of Arterial Hypertension f 
the European Society of Hypertension a d the European Society of Cardiology. 2007 Guidelines 
for the management of arterial hypertension: The Task Force for the Management of Arterial 
Hypertension f the European Society of Hypertension (ESH) and of the European Society 
of Cardiology (ESC) [published correction appears inJ Hypertens. 2007;25:1749]. J Hypertens. 
2007;25:1105-1187. 
2. Chobanian AV, Bakris GL, Black HR, et al, for the National Heart, Lung, and Blood Institute 
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure and the National High Blood Pressure Education Program Coordinating Committee. 
240 
E. MALACCO AND S. OMBONI  
The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure: JNC 7 report [published correction appears inJAMA. 
2003;290:197]. JAMA. 2003;289:2560-2572. 
3. Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N EnglJ 
Med. 2006;355:385-392. 
4. Pasini AF, Garbin U, Nava MC, et al. Effect of sulfhydryl and non-sulfhydryl angiotensin- 
converting enzyme inhibitors on endothelial function in essential hypertensive patients. AmJ 
Hypertens. 2007;20:443-450. 
5. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl 
angiotensin-converting e zyme inhibitor zofenopril.J Int MedRes. 2005;33:42-54. 
6. Altunoluk B, Soylemez H, Oguz F, et al. An angiotensin-converting e zyme inhibitor, zofeno- 
pril, prevents renal ischemia/reperfusion injury in rats. Ann Clin Lab Sci. 2006;36:326-332. 
7. Napoli C, Sica V, de Nigris F, et al. Sulfhydryl angiotensin-converting e zyme inhibition 
induces ustained reduction of systemic oxidative stress and improves the nitric oxide pathway 
in patients with essential hypertension. Am HeartJ. 2004;148:e5. 
8. Borghi C, Ambrosioni E, for the Survival of Myocardial Infarction Long-term Evaluation-2 
Working Party. Double-blind comparison between zofenopril and lisinopril in patients with 
acute myocardial infarction: Results of the Survival of Myocardial Infarction Long-term 
Evaluation-2 (SMILE-2) study. Am HeartJ. 2003;145:80-87. 
9. Borghi C, Bacchelli S, Esposti DD, et al, for the SMILE Study Investigators. Effects of the 
administration ofan angiotensin-converting e zyme inhibitor during the acute phase of myo- 
cardial infarction in patients with arterial hypertension. Survival of Myocardial Infarction Long- 
term Evaluation. AmJ Hypertens. 1999;12:665-672. 
10. Borghi C, Bacchelli S, Esposti DD, Ambrosioni E, for the SMILE Study. Effects of the early 
ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. 
Diabetes Care. 2003;26:1862-1868. 
11. Kelbaek H, Agner E, Wroblewski H, et al. Angiotensin converting enzyme inhibition at rest 
and during exercise in congestive heart failure. Eur HeartJ. 1993;14:692-695. 
12. Binkley PF, Haas GJ, Starling RC, et al. Sustained augmentation f parasympathetic tone with 
angiotensin-converting e zyme inhibition in patients with congestive heart failure. J Am Coll 
Cardiol. 1993;21:655-661. 
13. Elijovich F, Laffer CL, Schiffrin EL. The effects of atenolol and zofenopril on plasma trial natri- 
uretic peptide are due to their interactions with target organ damage of essential hypertensive 
patients.J Hum Hypertens. 1997;11:313-319. 
14. Leonetti G, Rappelli A, Omboni S, et al. A similar 24-h blood pressure control is obtained by 
zofenopril and candesartan i  primary hypertensive patients. Blood Press. 2006;15:18-26. 
15. Lacourci~re Y, Provencher P.Comparative effects of zofenopril and hydrochlorothiazide on office 
and ambulatory blood pressures in mild to moderate essential hypertension. BrJ Clin Pharmacol. 
1989;27:371-376. 
16. Malacco E, Piazza S, Omboni S, for the Zofenopril Study Group. Zofenopril versus lisinopril in 
the treatment of essential hypertension i  elderly patients: A randomised, ouble-blind, multi- 
centre study. Clin Drug Investig. 2005;25:175-182. 
17. Parati G, Omboni S, Malacco E, et al. Antihypertensive efficacy of zofenopril and hydrochloro- 
thiazide combination on ambulatory blood pressure. Blood Press. 2006;15:7-17. 
18. Zanchetti A, Parati G, Malacco E. Zofenopril plus hydrochlorothiazide: Combination therapy 
for the treatment of mild to moderate hypertension. Drugs. 2006;66:1107-1115. 
19. Malacco E, Omboni S. Antihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed 
combination for treatment in metabolic syndrome. Adv Ther. 2007;24:1006-1015. 
241 
CURRENT THERAPEUTIC  RESEARCH 
20. Conroy RM, Py/Sr~'l~i K, Fitzgerald AP, et al, for the SCORE Project Group. Estimation of 
ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur HeartJ. 2003; 
24:987-1003. 
21. Julius S, Kjeldsen SE, Weber M, et al, for the VALUE Trial Group. Outcomes in hypertensive 
patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The 
VALUE randomised trial. Lancet. 2004;363:2022-2031. 
22. Black HR, Elliott WJ, Grandits G, et al, for the CONVINCE Research Group. Principal results 
of the Controlled Onset Verapamil Investigation ofCardiovascular End Points (CONVINCE) 
trial. JAMA. 2003;289:2073-2082. 
23. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (The 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Major outcomes 
in high-risk hypertensive patients randomized to angiotensin-converting e zyme inhibitor or 
calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289:178 
and JAMA. 2004;291:2196]. JAMA. 2002;288:2981-2997. 
24. Ambmsioni E. Defining the role of zofenopril in the management of hypertension a d ischemic 
heart disorders. Am J Cardiovasc Drugs. 2007;7:17-24. 
ADDRESS CORRESPONDENCE TO:  Ettore Malacco, MD, Division of Internal 
Medicine, L. Sacco Hospital, Via G.B. Grassi 74, University of Milano, 20157 Milano, 
Italy. E-mail: ettore.malacco@tiscali.it 
242 
